Clostridium butyricum M588 (Miyarisan)
- Generic Name
- Clostridium butyricum M588 (Miyarisan)
Real-World AVION Study Affirms Avelumab Plus Axitinib Efficacy in Advanced Renal Cell Carcinoma
• The AVION study demonstrated that first-line avelumab plus axitinib is effective and safe for advanced renal cell carcinoma (RCC) in real-world settings.
• The 12-month overall survival rate was 82.7% among patients receiving the combination therapy, aligning with results from prior clinical trials.
• Common treatment-related adverse events included diarrhea, fatigue, and hypertension, with manageable safety profiles and stable health-related quality of life.
• These findings support the use of avelumab plus axitinib as a frontline treatment option for advanced RCC, reinforcing its clinical benefit.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath